Atossa Therapeutics Inc’s filing revealed that its Director Remmel H. Lawrence acquired Company’s shares for reported $7000.0 on Mar 26 ’25. In the deal valued at $0.70 per share,10,000 shares were bought. As a result of this transaction, Remmel H. Lawrence now holds 10,257 shares worth roughly $8205.6.
Maxim Group initiated its Atossa Therapeutics Inc [ATOS] rating to a Buy in a research note published on January 26, 2018; the price target was $2.
Price Performance Review of ATOS
On Tuesday, Atossa Therapeutics Inc [NASDAQ:ATOS] saw its stock jump 7.09% to $0.80. Over the last five days, the stock has gained 19.91%. Atossa Therapeutics Inc shares have fallen nearly -15.74% since the year began. Nevertheless, the stocks have fallen -47.66% over the past one year. While a 52-week high of $1.81 was reached on 01/03/25, a 52-week low of $0.55 was recorded on 04/07/25. SMA at 50 days reached $0.7122, while 200 days put it at $1.1091.
Levels Of Support And Resistance For ATOS Stock
The 24-hour chart illustrates a support level at 0.7402, which if violated will result in even more drops to 0.6849. On the upside, there is a resistance level at 0.8306. A further resistance level may holdings at 0.8657. The Relative Strength Index (RSI) on the 14-day chart is 64.00, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0929, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 6.00%. Stochastics %K at 91.80% indicates the stock is a selling.
How much short interest is there in Atossa Therapeutics Inc?
A steep rise in short interest was recorded in Atossa Therapeutics Inc stocks on 2025-04-15, dropping by -0.95 million shares to a total of 7.63 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-14 was 8.58 million shares. There was a decline of -12.51%, which implies that there is a negative sentiment for the stock.
